Synergistic regulatory effects of interleukin 6 and interleukin 1 on the growth and differentiation of human and mouse myeloid leukemic cell lines
- PMID: 2786454
Synergistic regulatory effects of interleukin 6 and interleukin 1 on the growth and differentiation of human and mouse myeloid leukemic cell lines
Abstract
We analyzed the effect of recombinant human interleukin 6 (IL-6), in combination with human recombinant interleukin 1 alpha (IL-1 alpha), on the growth and differentiation of several human and mouse myeloid leukemic cell lines, specifically U937, HL-60, M1, and its subclone M1-3b-N, into macrophage-like cells. IL-6 and IL-1 inhibited the growth of U937, M1, and M1-3b-N in a dose-dependent manner. Treatment of these cells with both IL-6 and IL-1 resulted in either an additive or a synergistic growth inhibition. IL-6 alone induced moderate differentiation of U937 and M1-3b-N, but the combination of IL-6 and IL-1 synergistically augmented this differentiation. In M1, only the combination of IL-1 and IL-6 resulted in differentiation. These two cytokines, whether alone or in combination, did not influence the growth and differentiation of HL-60. Therefore IL-6 in conjunction with IL-1 can induce differentiation in several human and mouse myeloid leukemic cell lines, although this effect varies with cell type. IL-6 did not stimulate the expression of IL-1 mRNA or IL-1 activity in U937 cells. IL-1 also failed to stimulate IL-6 production. Furthermore, the differentiation of U937 cells induced by IL-6 was not neutralized by antibody against either IL-1 alpha or IL-1 beta. The minimal differentiative effect of IL-1 was not affected by anti-IL-6 antibody. Therefore IL-6 and IL-1 appear to provide distinct signals for differentiation.
Similar articles
-
Synergistic interactions of interleukin 1, interferon-beta, and tumor necrosis factor in terminally differentiating a mouse myeloid leukemic cell line (M1). Evidence that interferon-beta is an autocrine differentiating factor.J Immunol. 1988 Jan 1;140(1):112-9. J Immunol. 1988. PMID: 3275716
-
Growth inhibition and augmentation of mouse myeloid leukemic cell line differentiation by interleukin 1.Cancer Res. 1987 May 1;47(9):2397-402. Cancer Res. 1987. PMID: 3494508
-
Effects of combinations of transforming growth factor-beta 1 and tumor necrosis factor on induction of differentiation of human myelogenous leukemic cell lines.J Immunol. 1990 Feb 15;144(4):1311-6. J Immunol. 1990. PMID: 2105994
-
Inhibition by interleukin 4 of leukemia inhibitory factor-, interleukin 6-, and dexamethasone-induced differentiation of mouse myeloid leukemia cells: role of c-myc and junB proto-oncogenes.Cancer Res. 1994 Jan 15;54(2):592-7. Cancer Res. 1994. PMID: 8275499
-
Molecular and cellular biology of interleukin-3.Immunol Ser. 1990;49:177-214. Immunol Ser. 1990. PMID: 2090251 Review.
Cited by
-
Chimeric antigen receptor-T cells with cytokine neutralizing capacity.Blood Adv. 2020 Apr 14;4(7):1419-1431. doi: 10.1182/bloodadvances.2019001287. Blood Adv. 2020. PMID: 32271901 Free PMC article.
-
Interleukin-6 is antiproliferative to a mouse hybridoma cell line and promotive for its antibody productivity.Cytotechnology. 1992;10(1):15-23. doi: 10.1007/BF00376096. Cytotechnology. 1992. PMID: 1369102
-
Regulation of c-fgr messenger RNA levels in U937 cells treated with different modulating agents.Immunology. 1992 May;76(1):65-71. Immunology. 1992. PMID: 1628903 Free PMC article.
-
Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression.Clin Exp Immunol. 1991 Jun;84(3):422-8. Clin Exp Immunol. 1991. PMID: 2044220 Free PMC article.
-
Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells.Cancer Immunol Immunother. 1993;36(2):101-7. doi: 10.1007/BF01754409. Cancer Immunol Immunother. 1993. PMID: 8425207 Free PMC article.